Aduro Announces Phase 2 Clinical Trial Results Demonstrating Statistically Significant Survival Benefit in Pancreatic Cancer Patients Treated with its

15-01-2014 Business Wire HealthComments (0)

Aduro BioTechBiotechnology

Aduro BioTech, Inc., a clinical stage biotechnology company, today announced the presentation of safety and efficacy data from a randomized Phase 2 clinical trial of its novel immunotherapy product candidates, CRS-207 and GVAX Pancreas, in metastatic pancreatic cancer patients. The trial was stopped early for meeting the primary efficacy endpoint at a pre-planned interim analysis. The data will be presented by Dung Le, M.D., Assistant Professor of Oncology at the

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top